Clinical Trial Update: Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ursolic acid as a countermeasure to muscle loss and insulin resistance in chronic spinal cord injury has completed, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance
• Muscular Atrophy
• Paraplegia
• Spinal Cord Injury
• Tetraplegia

Drugs mentioned

• Ursolic acid (ursolic acid)

Snippet

Sponsor: University of Miami | Conditions: Spinal Cord Injuries, Tetraplegia | Phase 2 | Status: COMPLETED | Results posted: 2025-05-21